Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors

Michael L. Megison, Lauren A. Gillory, Jerry E. Stewart, Hugh C. Nabers, Elizabeth Mroczek-Musulman, Alicia M. Waters, Jennifer M. Coleman, Virginia Kelly, James M. Markert, G. Yancey Gillespie, Gregory K. Friedman, Elizabeth A. Beierle

Research output: Contribution to journalArticlepeer-review

Abstract

Recently, investigators showed that mice with syngeneic murine gliomas that were treated with a neuroattenuated oncolytic herpes simplex virus-1 (oHSV), M002, had a significant increase in survival. M002 has deletions in both copies of the γ134.5 gene, enabling replication in tumor cells but precluding infection of normal cells. Previous studies have shown antitumor effects of other oHSV against a number of adult tumors including hepatocellular carcinoma and renal cell carcinoma. The purpose of the current study was to investigate the oncolytic potential of M002 against difficult to treat pediatric liver and kidney tumors. We showed that the oHSV, M002, infected, replicated, and decreased cell survival in hepatoblastoma, malignant rhabdoid kidney tumor, and renal sarcoma cell lines. In addition, we showed that in murine xenografts, treatment with M002 significantly increased survival and decreased tumor growth. Finally, these studies showed that the primary entry protein for oHSV, CD111 (nectin-1) was present in human hepatoblastoma and malignant rhabdoid kidney tumor specimens. We concluded that M002 effectively targeted these rare aggressive tumor types and that M002 may have potential for use in children with unresponsive or relapsed pediatric solid tumors.

Original languageEnglish (US)
Article numbere86843
JournalPloS one
Volume9
Issue number1
DOIs
StatePublished - Jan 30 2014
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Fingerprint

Dive into the research topics of 'Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors'. Together they form a unique fingerprint.

Cite this